Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314668 | 0.91 | NAMPT (0.35) | NAMPTDYRK1ATLR8TLR7MAP4K4 | |
| SCHEMBL29314700 | 0.90 | NAMPT (0.33) | NAMPTGSK3BDYRK1ATLR8TLR7 | |
| SCHEMBL29314664 | 0.88 | SCN9A (0.39) | SCN9A | |
| SCHEMBL29314649 | 0.87 | WNT1 (0.34) | NAMPTDYRK1ATLR8TLR7MAP4K4 | |
| SCHEMBL23037521 | 0.83 | NAMPT (0.37) | NAMPTSCN9ATLR8TLR7MAP4K4 | |
| SCHEMBL30539908 | 0.83 | NAMPT (0.37) | NAMPTSCN9ATLR8TLR7MAP4K4 | |
| SCHEMBL29314674 | 0.83 | ALDH1A1 (0.36) | NAMPTGSK3BDYRK1ATLR8TLR7 | |
| SCHEMBL29314682 | 0.83 | TLR8 (0.37) | NAMPTTLR8TLR7 | |
| SCHEMBL29314632 | 0.83 | ABL1 (0.45) | NAMPTMAP4K4 | |
| SCHEMBL29320672 | 0.82 | TLR8 (0.37) | NAMPTDYRK1ATLR8TLR7MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | NAMPT 122/4885GSK3B 815/4885DYRK1A 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.